Em PODCAST BBN Especial, os médicos Silvio Bromberg e Daniel Gimenes comentam alguns dos estudos que foram destaque na programação científica do San Antonio Breast Cancer Symposium 2022 (SABCS 2022), tanto na oncologia clínica, como no tratamento cirúrgico. Ouça.
Cirurgia:
Oncologia Clínica:
Referências:
Oncologia clínica
GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03 - Presenting Author: Sara A. Hurvitz, MD, FACP – University of California Los Angeles
Abstract GS2-01 - Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02 - Presenting Author: Ian Krop, MD, PhD – Dana-Farber Cancer Institute
Abstract GS2-03 - TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer - Presenting Author: Aditya Bardia, MD, MPH – Mass General Cancer Center, Harvard Medical School
GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting - Presenting Author: Aditya Bardia, MD, PhD, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA;
Abstract GS3-02 - Camizestrant, a next-generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial - Presenting Author: Mafalda Oliveira, MD, PhD – Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology
Abstract GS3-04 - Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial - Presenting Author: Nicholas Turner, MD, PhD – The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Cirurgia
PD15-08 Brazilian Randomized Study - BREAST-MRI Trial - Impact of Preoperative Magnetic Resonance in the Evaluation for Breast Cancer Conservative Surgery: Local recurrence and surgical outcomes - Presenting Author: Bruna S. Mota, MD, PhD, Physician Assistant - Instituto do Cancer do Estado de São Paulo;
PD15-11 Axillary dissection to determine nodal burden to inform systemic therapy recommendations in patients with clinically node-positive breast cancer: Pre-planned substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101) - Presenting Author: Walter P. Weber, MD, Chief Physician - Breast Center, University Hospital of Basel, Basel, Switzerland
PD15-04 Overall survival following breast conserving surgery and adjuvant radiotherapy compared with mastectomy for early stage breast cancer: a systematic review and metaanalysis - Presenting Author: Kiran Kasper Rajan, MBBS MSc, Academic Foundation Doctor - Bristol Medical School
PD15-12 A pre-surgical window trial of oral tamoxifen versus transdermal 4-hydroxytamoxifen gel in women with estrogen receptor positive duct carcinoma in situ (DCIS) - Presenting Author: Oukseub Lee, Ph.D., Research assistant professor - Northwestern University
Abstract GS4-01 - Impact of Breast Conservation Therapy on Local Recurrence in Patients with Multiple Ipsilateral Breast Cancer – Results from ACOSOG Z11102 (Alliance) - Presenting Author: Judy C. Boughey, MD – Mayo Clinic
GS4-02 Oncological Outcomes Following Omission of Axillary Lymph Node Dissection in Node Positive Patients Downstaging To Node Negative with Neoadjuvant Chemotherapy: the OPBC-04/EUBREAST-06/OMA study - Presenting Author: Giacomo Montagna, MD, MPH, Breast Surgeon - Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
